$OTLK News

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Outlook Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation

BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call

Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Why Did OTLK Stock Crash In Pre-Market Today?